WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II FORWARD-53 trial. Wave plans to file for accelerated approval of the candidate in ...

Wave Life Sciences is preparing to seek Food and Drug Administration approval of its therapy for Duchenne muscular dystrophy after claiming success in a Phase 2 study. After discussions with FDA ...

Investing.com -- Shares of Wave Life Sciences Ltd . (NASDAQ:WVE) rose 14% today, following the company’s announcement of positive results from its FORWARD-53 clinical trial in Duchenne muscular ...

THE WEEK’S MOST POPULAR CURRENT RAP SONGS ACROSS ALL GENRES, RANKED BY STREAMING ACTIVITY DATA BY ONLINE MUSIC SOURCES TRACKED BY LUMINATE, RADIO AIRPLAY AUDIENCE IMPRESSIONS AS MEASURED ...